Brokers Set Expectations for Fate Therapeutics, Inc.’s Q1 2024 Earnings (NASDAQ:FATE)

Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Stock analysts at Wedbush upped their Q1 2024 EPS estimates for shares of Fate Therapeutics in a report issued on Monday, February 26th. Wedbush analyst D. Nierengarten now forecasts that the biopharmaceutical company will post earnings per share of ($0.49) for the quarter, up from their prior […]

Leave a Reply

Your email address will not be published.

Previous post Shoals Technologies Group, Inc. (NASDAQ:SHLS) Receives $25.50 Average PT from Brokerages
Next post Investors Buy Large Volume of TJX Companies Call Options (NYSE:TJX)